montefiore hospital new york research

• Find a Doctor

Research and Clinical Trials

Science and medicine advancing human health.

At Montefiore Einstein, our world-renowned researchers are making strides every day toward groundbreaking scientific and clinical discoveries that create a healthier future for all. 

We actively contribute to hundreds of research initiatives, from basic science to all phases of clinical trials, to translate scientific breakthroughs into cutting-edge diagnostics and treatments.  

Together, Montefiore Einstein’s clinician scientists, investigators and volunteers are working tirelessly to advance human health. 

Research and Discovery at Albert Einstein College of Medicine

Teams comprised of faculty and students work together to achieve breakthroughs in biomedical and translational science — a foundation of excellence that clinical studies can build on.

Leaders in Clinical Innovation

Our physician scientists work independently and collaborate closely with fellow investigators across Montefiore Einstein to advance and redefine treatments and care.

To learn more about research and innovation from our centers of excellence and clinical programs, select from the list below.

• The AIDS Center
• Allergy & Immunology
• Alzheimer's Disease
• Anesthesiology
• Arthritis & Joint Disease
• Asthma Center
• Blood (Hematology)
• Bones, Muscles & Joints (Orthopaedics)
• Brain (Neurology)
• Cancer (Oncology)
• Cardiothoracic Surgery
• Craniofacial Surgery
• Critical Care Medicine
• Dentistry & Oral Surgery
• Dermatology
• Emergency Medicine
• Endocrinology
• Family & Social Medicine
• Fetal Medicine
• Gastroenterology
• General Internal Medicine
• Headache Center
• Heart (Cardiology & Vascular)
• ICU (Critical Care Medicine)
• Infectious Diseases
• Neurological Surgery
• OB/GYN & Women's Health
• Ophthalmology and Visual Sciences
• Orthopedics
• Otorhinolaryngology (ENT)
• Psychiatry and Behavioral Sciences
• Pulmonary Medicine
• Rehabilitation Medicine
• Rheumatology
• Transplantation
• Vascular Surgery

Research News

Montefiore einstein neurosurgery: at the forefront of treating brain aneurysms with a state-of-the-art endovascular device, neurocognitive impairments, meth use, and people with hiv, montefiore einstein celebrates opening of psychiatry research institute, understanding the cause of coma in cerebral malaria, clinical trials.

Clinical trials are medical research studies that evaluate the safety and effectiveness of all kinds of drugs and treatments. This trial process is the primary route for advancing our medical knowledge and helping people everywhere live longer, healthier lives. Nearly every pharmaceutical, diagnostic test and medical device we use today was developed through a series of clinical trials.   

These clinical trials are not possible without our volunteers. Having a diverse group of research participants helps researchers understand how results may apply to everyone who may receive the drug, treatment or device in the future.

Learn more about clinical trials

Find a Clinical Trial

Trials by category.

Frequently searched categories  

Blood Disorders

Brain, spinal cord & nervous system, asthma and other respiratory diseases, heart/cardiovascular.

• View all categories

Clinical Trials Frequently Asked Questions

Learn more about clinical trials and what it’s like to participate in one. Taking part in a clinical trial can make a difference today – and for the future of medicine.

Research Resources for Montefiore Einstein Professionals

Our investigators are committed to sharing resources with other medical professionals to advance human health and scientific discovery.

Institute for Clinical and Translational Research (ICTR)

Human subject research project navigation tool, elsevier research profiles, office of clinical trials (oct), office of human research affairs (ohra), biomedical research alliance of new york (brany).

• Find a Doctor

Information on our masking guidelines.

Información sobre nuestras normas de uso de mascarilla.

New research. New discoveries. New options.

We are among the elite 1% nci comprehensive cancer centers in the u.s. — and we are ranked in the top 1% of all u.s. hospitals for cancer care, according to u.s. news & world report ., types of cancer we treat.

• See All Cancer Types

Cancer Clinical Trials

• Blood & Bone Marrow Cancers
• Brain, Spine & Central Nervous System Cancers
• Breast Cancer
• Childhood Cancers
• Endocrine System Cancers
• Gastrointestinal (GI) Cancers
• Genitourinary (GU) & Urologic Cancers
• Gynecologic Cancers
• Head & Neck Cancers
• Kaposi Sarcoma & AIDS-Related Cancers
• Lung & Chest Cancers
• Prostate Cancer
• Skin Cancer

Treating More Than 200 Types of Cancer Over 320 Active Clinical Trials

Navigating your cancer care.

At Montefiore Einstein Comprehensive Cancer Center, you receive evidence-based cancer care that addresses the unique needs of each individual patient. Our NCI-designated comprehensive cancer center brings the worlds of clinical care and academic research together and allows for the translation of novel, leading-edge scientific discoveries into improved clinical outcomes and new life-saving treatments.

Using a multidisciplinary team of disease-focused experts, our full-service cancer center is focused on the prevention, early diagnosis and treatment of cancer while incorporating a comprehensive spectrum of traditional and holistic care. This allows us to deliver highly specialized and coordinated compassionate care for the whole person, address complex medical needs and improve the quality of life for each and every patient.

• Get Started

Over 50 Years of Cancer Research and Treatment Breakthroughs

Our latest research, advancing human health, scientific discovery and innovation through cancer research.

• View Our Research

September, 2023

Montefiore Einstein Comprehensive Cancer Center is honored to be recognized for its unique and special contributions as one of the nation’s 56 NCI-designated comprehensive cancer centers

November 20, 2023

Hope for Eradicating Dormant but Deadly Cancer Cells

November 03, 2023

Montefiore Einstein Comprehensive Cancer Center One of the First to Bring CAR T-Cell Therapy with 90% Response Rate to Multiple Myeloma Patients from Minority and Underrepresented Racial and Ethnic Groups (URG)

Leaders in the science of cancer care.

At Montefiore Einstein Comprehensive Cancer Center, we’re committed to finding new and better cancer treatment options.   Our research breakthroughs continue to lead to game-changing cancer treatment practices and give patients a chance to join upcoming clinical trials, which may offer potentially successful treatment options. We’ve received accreditation from the NCI for the past 50 years in a row. Our facility is one of only 71 NCI-designated centers across the United States-and the only one located between Manhattan and New Haven. We made that expansion from Manhattan to Westchester to provide convenient access to cancer patients across the region.

State-of-the-Art Technology

At Montefiore Einstein Comprehensive Cancer Center, we are proud to provide patients with the newest technology available and offer the latest surgical and therapeutic techniques. Our goal is to utilize the least invasive solutions for your cancer care.

That is why we offer the latest in image-guided, immuno-, cellular and targeted therapies, to name just a few.

Some of our other molecular imaging technology includes the latest three-dimensional systems for bioluminescence imaging (BLI), fluorescence molecular imaging (FMI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT).

Committed to Moving Faster Than Cancer

Cancer center highlights report.

Our Highlights Report documents our remarkable innovations in research, treatment and care.

in cancer relevant funding, of which $33 million is dedicated to philanthropy

patients enrolled in clinical research studies

papers published annually in high impact peer-reviewed journals

types of cancer treated

See how the past couple of years have been a remarkable time of vision and growth.

Meet your cancer care team.

Montefiore Einstein Comprehensive Cancer Center is home to 14 teams of award-winning, multidisciplinary experts who will develop a highly personalized treatment plan specific to your particular type of cancer, including those considered rare.

• Meet the Team

Schedule a Consultation.

Consultations are available in person, by phone or by video visit.

Contact us today to schedule a consultation.

Events at Montefiore Einstein Comprehensive Cancer Center

Screenings & prevention, community events & education calendar, featured cancer clinical trials.

• Digestive System Diseases
• Gastrointestinal Diseases
• Colonic Diseases
• Immune Checkpoint Inhibitors
• Atezolizumab

A Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer (STELLAR-303)

Colorectal Cancer

• Neoplastic Processes
• Pathologic Processes
• Neoplasm Metastasis

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer

• Lung Diseases
• Respiratory Tract Diseases
• Bronchial Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Antimitotic Agents

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (CA209-6K6)

Resectable Stage IIA to IIIB Non-Small Cell Lung Cancer

• Nervous System Neoplasms
• Brain Diseases

Phase I Study of Fractionated Stereotactic Radiation Therapy

Brain Metastases

• Neuroepithelial
• Neuroectodermal Tumors
• Antineoplastic Agents

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

• Respiratory Tract Neoplasms
• Glioblastoma

A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer Conditions: Non-Small Cell Lung Cancer; Glioblastoma multiforme

Non-Small Cell Lung Cancer, Glioblastoma multiforme

• Antiemetics
• Antimetabolites
• Dexamethasone

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)

Sarcomas, Cancer, Gatrointestinal (GI) Cancers

Your generosity makes a difference.

Montefiore Einstein Comprehensive Cancer Center

Edward Chu, M.D., M.M.S., Director

Bronx, New York

Main: 718-862-8840

Visit Website

Montefiore Einstein Comprehensive Cancer Center (MECCC), at the Albert Einstein College of Medicine and Montefiore Medical Center, is a national leader in cancer research and clinical care located in the heart of Bronx, NY, one of the nation’s most ethnically diverse areas. Founded in 1971 and designated as an NCI Cancer Center in 1972 (the country’s fourth), MECCC combines the exceptional science of the Albert Einstein College of Medicine with the multidisciplinary clinical care of the Montefiore Health System. The mission of MECCC is to serve the unique cancer-related needs of one of the most diverse and socioeconomically disadvantaged populations in the U.S. and to reduce the burden of cancer in the Bronx and the nation through exceptional cancer research, education and training, and community outreach and engagement, as well as through the delivery of compassionate leading-edge care for all -  including historically marginalized communities that face heightened inequities in cancer and social determinants of health.  

Research at Montefiore Einstein Comprehensive Cancer Center 

MECCC works to reduce the burden of cancer in its Bronx catchment area and beyond through novel transdisciplinary research in four distinct research program areas linked by four cross-cutting themes: cancer disparities and inequities in the Bronx; tumor and organ microenvironments; molecular variations as determinants of outcome; and prevention, early detection, and interception of primary and recurrent disease. MECCC has more than 195 members who engage in research in the following scientific areas:  

• The Tumor Microenvironment and Metastasis (TMM) Program aims to catalyze basic research at MECCC and elsewhere that addresses the mechanisms by which cancer cell intrinsic and microenvironmental signals conspire to fuel cancer cell dissemination, persistence during dormancy and metastatic outgrowth in target organs. By elucidating each stage of the metastatic process, investigators aim to identify novel therapeutic targets and biomarkers that will help personalize the prevention and treatment of the metastatic process.  
• Stem Cell and Cancer Biology (SCCB) Program aims to discover new therapeutic targets in cancer. They are looking for ways to identify novel mechanisms of lineage specification with relevance to cancer stem cell function as well as to understand cancer evolution and therapy resistance—and identify unique vulnerabilities in cancer cells.
• The Cancer Therapeutics (CT) Program aims to develop and implement innovative strategies for the discovery, design, and development of novel anticancer agents, combination regimens, and/or therapy-focused technologies. Through intensive collaboration with other MECCC research programs and outside collaborators, CT serves as the hub that integrates and advances preclinical science and discoveries into early-phase clinical trials.  
• Scientists in the Cancer Epidemiology, Prevention & Control (CEPC) Program investigate behavioral, environmental, and molecular risk at the root of the development of cancer. In addition to characterizing risk factors that drive or contribute to cancer health disparities in MECCC’s catchment area (viral causes such as HPV and HIV, hormonal factors, obesity and inflammation, and genetic/epigenetic factors), CEPC scientists are focused on improving cancer prevention and screening efforts among vulnerable and high-risk groups and developing innovative strategies to reduce health inequities and enhance cancer care delivery, survivorship, and outcomes. CEPC plays a pivotal role in the Cancer Center’s public health mission and is tightly integrated with our community outreach and engagement initiatives.  

MECCC’s strength in clinical research is underscored by its annual enrollment of more than 1,000 patients in the Cancer Center’s 320+ active clinical trials, many of which are focused on investigator-initiated, bench to bedside early-phase clinical trials. 

Select Scientific Initiatives at Montefiore Einstein Comprehensive Cancer Center

MECCC has been a leader in cancer-focused research, with seminal discoveries published in high-impact journals. Its track record of major accomplishments in basic, translational, clinical, and population sciences as well as community outreach and engagement, have been paradigm-shifting, practice-changing, and policy impacting. Select achievements include: 

• Discovered the mechanism of action for the microtubule inhibitor paclitaxel, which led to the widespread clinical use of Taxol and its application in cancer therapeutics worldwide.
• Developed novel transition state inhibitors by exploring transition state structures for specific enzyme targets. These studies have led to the approval of forodesine (BCX1777) for peripheral T-cell lymphoma (PTCL) in Japan and to the development of transition state inhibitors for MTAP, MAT2A, and MTAN to be used alone or in combination with other agents to treat human cancers.
• Identified the critical importance of the TGF-ß pathway in the pathogenesis of MDS, which then provided the rationale for the clinical development of novel TGF-ß inhibitors.  
• Developed phosphatase inhibitor menadione (vitamin K3) as a novel agent to protect and/or treat the skin toxicity associated with agents that target the epidermal growth factor receptor (EGFR).  
• Chaired the landmark TAILORx clinical trial that used the Oncotype DX Recurrence Score in clinical decision-making for adjuvant therapy of women with early-stage ER-positive, HER2-negative breast cancer. This practice-changing study demonstrated that the recurrence rate with endocrine therapy alone in low-risk patients was sufficiently low so that these patients could be spared systemic chemotherapy. 
• Identified potential biomarkers for pinpointing the subset of patients with ER+/HER2- breast cancer who have an increased risk for developing metastatic disease.  
• Made key contributions to the development of CAR T-cell programs that led to the clinical trials pivotal for approval of axicabtagene ciloleucel (Yescarta) for mantle cell lymphoma. 
• Confirmed that CART-T therapy for various blood cancers is equally effective in Black and Hispanic patients, with no statistical difference in clinical outcomes or side effects, when compared to White non-Hispanic patients.  
• Published findings that residual ER-positive breast cancer following preoperative chemotherapy represents a risk factor for worse outcomes in Black women but not in White women—possibly because of biological differences in how the tumor microenvironment responds to chemotherapy. 
• Developed a first-in-class BAX activator as a novel paradigm for inducing apoptosis in cancer that can be used alone or in combination with BCL-2/BCL-Xl inhibitors for treating human cancers.
• Developed a novel class of immunomodulatory biologics using the synTac platform that provides a unique opportunity for the facile replacement of the antigenic peptide to realize a wide range of biologics that are specifically tuned to a patient’s individualized neoantigens.
• Described how primary tumor niches termed TMEM doorways composed by specialized tumor cells, macrophages and endothelial cells in the tumor, instruct precursors of breast cancer DCCs to turn on stem and dormancy programs driven by NR2F1 and SOX9. 
• Discovered a new human immune checkpoint pathway involving the HHLA2 ligand and the KIR3DL3 receptor, a KIR family member. The HHLA2-KIR3DL3 pathway is expressed in a broad spectrum of human cancers, particularly in PD-L1 negative cancers. As such, disruption of HHLA2-KIR3DL3 is an attractive new approach for PD-L1 negative cancer patients who do not respond to anti-PD-1/PD-L1 therapy.
• Identified a higher burden of clonal hematopoiesis and leukemia associated mutations in WTC-exposed firefighters when compared to non-WTC-exposed firefighters. 
• Provided compelling evidence for continuing the Medical Monitoring and Treatment (MMTP) and for providing no-cost cancer screening for WTC first responders. This research has contributed to major policy decisions regarding monitoring and care of WTC first responders.
• Incorporated web-based tobacco smoking interventions into standard practice as well as in national clinical guidelines for people living with HIV (PLWH).
• Demonstrated that primary HPV screening with reflex HVP18/18-genotyping resulted in fewer unnecessary colposcopies. This research supports the use of molecular cervical cancer screening in women living with HIV, and these studies have contributed to national guidelines on cervical cancer screening. 
• Research conducted by MECCC population science investigators are informing policy and building capacity in all areas needed to implement comprehensive cervical cancer screening and treatment in Rwanda, Democratic Republic of Congo, and Cameroon.  

This profile was provided by Montefiore Einstein Comprehensive Cancer Center.

• Make A Gift
• Pay My Bill
• Schedule An Appointment
• Find a Doctor
• Our Services

Our Experts

• Screening & Diagnosis
• For Patients
• Male Breast Cancer
• Advanced Cardiac Imaging
• Cardiopulmonary Rehabilitation
• Congestive Heart Failure
• Interventional Cardiology
• Chest Pain Center
• Express Care
• Pediatric ED
• Stroke Center
• Trauma Center
• Diagnosis & Treatment
• Schedule a Tour
• Nutrition Counseling
• Application Process
• For Patients 
• Nondiscrimination
• Diversity, Equity and Inclusion
• Surgical Procedures
• Types of Surgeries
• Good Faith Estimate
• Hospital and Professional Charges
• Price Transparency
• Online Bill Pay
• Financial Aid Policy
• Medical Records
• Patient Amenities
• Pastoral Care
• Interpretation Services
• Registration
• Service Animals

Secure access to your healthcare information.

• eNewsletter
• Health Blog
• HealthWorks Magazine
• Classes & Events
• Community Assessment & Service Plan
• Community Education
• Healthy Recipes
• Employee Assistance Programs for Businesses
• Montefiore Nyack Foundation
• Speakers Bureau

We offer many events, classes, and support groups to enrich the lives of our neighbors. To learn about our Outreach Programs and  calendar of events,

• Pastoral Care & Chapel
• Send a Cheer Card
• We Care Standards
• 125th Anniversary
• Hospital Directory
• Hospital Leadership
• Current Job Openings
• Philosophy of Caring
• Goals for Nursing
• Press Releases
• Responding to Complaints
• Reporting Complaints
• Complaint Evaluations
• Workplace Safety
• Billing & Coding
• Human Resources
• Resource Management
• Laws & Regulations
• Patient Care
• Center for Learning & Development
• Our Top Docs
• Continuing Medical Education
• Volunteering

We offer excellent opportunities to advance your career while enjoying a competitive salary and robust benefits.

At Montefiore Nyack Hospital, medical oncologists, cancer surgeons and radiation oncologists partner in caring for patients with all types of cancer and blood disorders. Our physicians are board-certified and fellowship trained in oncology, providing patients with the highest level of excellence in cancer care.

In addition to physicians who are cancer experts, our team includes nurse navigators, social workers, dieticians, pharmacists, financial counselors and pastoral care representatives who are also highly experienced in caring for cancer patients.

Our multidisciplinary team meets with newly diagnosed patients to help them through the entire cancer process, from diagnosis and treatment to support and education.

Carla Laureano Lal, MSN, FNP-C

Jobs at Montefiore Medical Center

• Montefiore Information Technology
• Pharmacy Jobs
• Corporate/Administrative Jobs
• Nursing Jobs
• Allied Health Jobs
• Physician Jobs
• Laboratory Jobs
• Physician Assistant Jobs
• Hudson Valley Jobs
• View all Jobs
• DIVERSITY, EQUITY & INCLUSION
• CURRENT EMPLOYEES

CREATE THE FUTURE OF HEALTHCARE

Montefiore, the University Hospital for Albert Einstein College of Medicine, is one of nation's largest academic medical centers. Those who work here are driven by a passion to serve and a desire to provide excellent care to all. We are a growing organization and one of New York’s top employers.  Join us as we further our reputation as a leader in clinical care, healthcare research, education and social commitment.

Nurse Recruitment Hotline: 718-920-6697 ; Monday-Friday: 9am-4pm.  

Nurse Recruitment Hotline: 718-920-6697 ; Monday-Friday: 9am-4pm

WHY TOP TALENT PICKS MONTEFIORE

Since its inception in 1884, Montefiore’s mission has been to heal, to teach, to discover and advance the health of the communities we serve.

Montefiore's state-of-the-art facilities include the internationally-recognized Children’s Hospital at Montefiore and our Notable Centers of Excellence - Montefiore Einstein Center for Cancer Care, Montefiore Einstein Center for Heart and Vascular Care, Montefiore Einstein Center for Transplantation. Combined with a growing number of locations for primary and specialty care throughout the Bronx and Westchester County, Montefiore is the ideal organization to apply and hone your expertise.

FEATURED JOB CATEGORIES

• Job Searches
• Privacy Policy
• Workplace Postings
• Montefiore.org
• Einstein.org

© Copyright 2019

• Awards + Events
• Architecture
• Interior Design
• Construction and Engineering
• Operations and Facility Management
• Research and Theory
• Perspectives
• White Papers
• Ambulatory Care / Clinics
• Behavioral Health
• Cancer Care
• Emergency / Urgent Care
• Specialty Projects
• Landscaping / Exteriors
• FEATURED FIRMS
• Healthcare Design Showcase
• Breaking Through
• Remodel/Renovation Competition
• The HCD 10: Celebrating Healthcare Design Leaders
• HCD Product Innovation Awards
• HCD Conference + Expo
• Nightingale Awards
• Rising Star Competition
• HCD Webinar Schedule
• Furniture and Casegoods
• Building Products
• Ceiling and Wall Systems
• Infection Control

Montefiore Files Certificate Of Need To Build New ICU In Bronx, New York

Montefiore Medical Center in New York has filed a certificate of need with the New York State Department of Health (New York) for an intensive care unit (ICU) renovation at its Henry and Lucy Moses Division hospital in Bronx, N.Y., according to beckershospitalreview.com .

The proposed $15 million project would transform a medical/surgical unit on the hospital’s seventh floor into a 21-bed ICU.

For more news on Montefiore, go here .

Latest News

Kai 360 construction services adds new team member, avera plans two campus expansion projects in sioux falls, south dakota, chi memorial breaks ground on new hospital in ringgold, georgia, aspirus health plans $40m expansion project in merrill, wisconsin.

Citi to Lay off 430 Employees in New York Across Units

FILE PHOTO: Workers exit the Citi Headquarters in New York, U.S., January 22, 2024. REUTERS/Brendan McDermid/File Photo

(Reuters) -Citigroup will lay off 430 employees across different divisions in New York, the bank disclosed in filings with the State Department of Labor on Monday.

The layoffs will impact 363 employees of the lender's primary banking unit, Citibank. Workers in the technology and broker-dealer arm will also be affected, the filings showed.

The bank last week ended a sweeping overhaul, its biggest in decades, as part of an effort to simplify its structure and improve performance.

Unveiled in September, the reorganization reduced management layers to eight from 13 as part of an effort to cut bureaucracy. Citi has also set a goal to trim its global workforce by 20,000 over the next two years.

The lender did not immediately respond to a request for additional comment. The latest layoffs are scheduled for June, according to the filings.

The bank's CEO, Jane Fraser, said in January that Citi had cut 1,500 managerial roles, comprising 13% of its worldwide leaders. The changes would create annual savings of about $1 billion, she said at the time.

Citi has been looking to boost its profits and stock performance, which has lagged those of its rivals. Wells Fargo analyst Mike Mayo, who has rated Citi's stock as his top pick, had previously said that 2024 was part of a "multi-decade inflection point" for the bank.

So far this year, Citi's stock has gained nearly 23% as of last week's close, outperforming rivals JPMorgan Chase, Bank of America and Wells Fargo. It has also fared better than the S&P 500 banks index, which has gained 14.4%.

(Reporting by Niket Nishant in Bengaluru; Editing by Anil D'Silva)

Copyright 2024 Thomson Reuters .

Tags: United States

The Best Financial Tools for You

Credit Cards

Personal Loans

Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved or endorsed by any other entities, such as banks, credit card issuers or travel companies. The content on this page is accurate as of the posting date; however, some of our partner offers may have expired.

Subscribe to our daily newsletter to get investing advice, rankings and stock market news.

See a newsletter example .

You May Also Like

Will the stock market crash.

Brian O'Connell April 1, 2024

10 of the Best-Performing 401(k) Funds

Coryanne Hicks April 1, 2024

Bridge Collapse Disrupts Coal Trade

Matt Whittaker April 1, 2024

2024's 10 Best-Performing Stocks

Wayne Duggan April 1, 2024

Best REIT ETFs to Buy and Hold for 2024

Glenn Fydenkevez March 29, 2024

9 Highest Dividend Stocks in the S&P 500

Jeff Reeves March 29, 2024

5 of the Best Stocks to Buy Now

Ian Bezek March 29, 2024

Handling Extra Portfolio Risk

Kate Stalter March 29, 2024

7 Best Copper Stocks to Buy

Glenn Fydenkevez March 28, 2024

11 New Spot Bitcoin ETFs to Buy in 2024

Tony Dong March 28, 2024

Is M&A Activity Set to Spike in 2024?

Scott Ward March 28, 2024

7 Oversold Tech Stocks to Buy

Wayne Duggan March 28, 2024

7 Top Gene-Editing Stocks to Buy

Wayne Duggan March 27, 2024

7 Best Preferred Stock ETFs to Buy Now

Tony Dong March 27, 2024

Fixed Index Annuity Is Making a Comeback

Marguerita Cheng March 27, 2024

9 Growth Stocks for the Next 10 Years

Jeff Reeves March 27, 2024

5 Best Short-Term Investments for Income

Tony Dong March 26, 2024

10 Best Health Care Stocks to Buy

Wayne Duggan March 26, 2024

Best Micro-Cap Stocks for 2024

Marc Guberti March 26, 2024

Vanguard Funds for Beginners